Back to Search
EASTER FLOYD, PHARMD
PHARMD
Pharmacist
NPI: 1629316146Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
PS42670(FL)
Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist
Pharmacist — Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist
Code: 1835P0018X
PS42670(FL)
Research & Publications (18)
Acute, sublethal exposure to a pyrethroid insecticide alters behavior, growth, and predation risk in larvae of the fathead minnow (Pimephales promelas).
PMID 18380520·Environ Toxicol Chem·2008
7-preclinical
Psychometric properties of the Sutter-Eyberg Student Behavior Inventory with rural middle school and high school children.
PMID 14994955·Assessment·2004
4-observational
Isolation of human adipose-derived stem cells from biopsies and liposuction specimens.
PMID 18370084·Methods Mol Biol·2008
8-other
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
PMID 17942920·Cancer Res·2007
7-preclinical
MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
PMID 17329684·Radiology·2007
7-preclinical
Pathway analysis using random forests classification and regression.
PMID 16809386·Bioinformatics·2006
7-preclinical
Acute drug-induced vascular injury in beagle dogs: pathology and correlating genomic expression.
PMID 16507541·Toxicol Pathol·2006
7-preclinical
Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation.
PMID 16012822·Eur Radiol·2005
7-preclinical
The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors.
PMID 15905721·Invest Radiol·2005
1-meta
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
PMID 14612527·Cancer Res·2003
7-preclinical
MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
PMID 12722742·Eur J Nucl Med Mol Imaging·2003
4-observational
MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model.
PMID 12188326·Acad Radiol·2002
3-trial
Dynamic MRI enhanced with albumin-(Gd-DTPA)30 or ultrasmall superparamagnetic iron oxide particles (NC100150 injection) for the measurement of microvessel permeability in experimental breast tumors.
PMID 12019843·Acad Radiol·2002
4-observational
MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlations to histopathology.
PMID 11536400·J Magn Reson Imaging·2001
7-preclinical
The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma.
PMID 11419179·Cancer Immunol Immunother·2001
7-preclinical
Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model.
PMID 11382948·J Magn Reson Imaging·2001
4-observational
Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlations to histopathology.
PMID 11323815·Magn Reson Med·2001
4-observational
MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation.
PMID 11161179·Radiology·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1800 NW 10TH AVE, 1ST FLOOR, ELLIOTT BLDG
MIAMI, FL 33136 - Phone
- (305) 243-3839
Quick Facts
- NPI
- 1629316146
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 18
Are you this provider?
Claim Your Profile